Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancerResponse to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors